New issue of #BloodAdvances out now featuring Monovalent antibody treatment of von Willebrand disease, Osteocyte-derived erythroferrone regulates liver hepcidin during stress erythropoiesis, and more. Explore here: ashpublications.org/bloodadvance...

New issue of Blood Advances out now! Featuring Advancing systems-based hematology, A new era for heavy menstrual bleeding, The interplay of von Willebrand disease and women’s reproductive health, and more. Explore here: ashpublications.org/bloodadvance... #BloodAdvances

Treatment of von Willebrand disease Abstract. Treatment for von Willebrand disease (VWD), the most common inherited bleeding disorder, has advanced considerably since its initial description

In continued observance of Bleeding Disorders Awareness Month, we're highlighting an important article from Blood Advances on the treatment of von Willebrand Disease: ashpublications.org/bloodadvance...
#vonwillebranddisease #BDAM #bloodadvances

New issue of Blood Advances out now! Featuring Emerging from the shadows of congenital TTP, Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia, and more. Explore: ashpublications.org/bloodadvance... #BloodAdvances

New issue of Blood Advances out now featuring: FLT3-ITD measurable residual disease from the QuANTUM-First trial, Low bone mineral density and pain impact in adults with SCD, Antibiotic risk score for acute graft-versus-host disease and more. ashpublications.org/bloodadvance... #BloodAdvances

Bispecific antibodies appear to be a promising therapeutic option, offering durable responses compared to chemotherapy and targeted therapy. Read the full article in Blood Advances: buff.ly/19Ev4Ai #MCL #BloodAdvances

AI reduces manual analysis time for the detection of MRD to 1 minute per case, on average. Read the full study in Blood Advances: buff.ly/NG1Zlty #AI #BloodAdvances

New issue of Blood Advances out now featuring MRD assessment by flow cytometry in B-ALL made easier, Targeting the lectin pathway in TA-TMA, AI-generated peptides for research and clinical practice, and more. Explore here: ow.ly/6UUP50XWfXv #BloodAdvances #NewIssue

'Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis' read in Blood Advances: buff.ly/kzxbRAk #bloodadvances

We're excited to share that Blood Advances has a new Associate Editor, Dr. Steven Lane. He's a clinical hematologist and researcher at Royal Brisbane & Women's Hospital and runs a busy research group at the Queensland Institute of Medical Research. Welcome Dr. Lane! #BloodAdvances

CD8+ T-cell activation, function, and metabolic reprogramming are suppressed by hypoxia, linked to decreased mTOR activity. Read in Blood Advances: buff.ly/ttZb0at #BloodAdvances #MultipleMyeloma

New issue of Blood Advances out now featuring A tale of 2 mice, Reporting infections in cellular therapies, Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations, and more. ashpublications.org/bloodadvance... #BloodAdvances

Welcome to #ASH25! We have a Special Annual Meeting Edition of Blood Advances. Be sure to pick up your free copy this weekend at the ASH Booth (1101) or throughout the convention center. #BloodAdvances #AnnualMeeting #Hemesky

Explore the new issue of Blood Advances, featuring FcR γ-chain and platelet hyperactivity, Deferral of immunosuppression in acquired hemophilia, Diagnosis of von Willebrand disease and more. ashpublications.org/bloodadvance... #BloodAdvances #NewIssue #Hemesky

A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL Key PointsLEN with DA–EPOCH-R had a complete response rate of 83.6% in patients with DHL and DEL with no unexpected toxicities.With a median follow-up of 3

LEN with DA–EPOCH-R had a complete response rate of 83.6% in patients with DHL and DEL with no unexpected toxicities. Read in Blood Advances: buff.ly/NUvoHSQ #BloodAdvances #Hemesky

LinkedIn This link will take you to a page that’s not on LinkedIn

Just out in #bloodadvances: our analysis from the Uniklinik RWTH Aachen-based German Aplastic Anemia / Bone marrow failure (AA/BMF) registry: „Late-Onset Telomere Biology Disorders …“ - lnkd.in/eKfervB6 #ScholarAlerts @TeamTelomereInc @lichterzellen @AAundPNHeV @aamdsif @ESHaematology #eshbmfs2026

Great to have you here! Should we expect your journals to join BlueSky soon too? #Blood #BloodAdvances #BloodNeoplasia